Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2Connie Celum, Lawrence Corey, Elizabeth A. Bukusi et al.|New England Journal of Medicine|2010Cited by 526
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Frank Tomaka et al.|The Lancet|2018Cited by 342
Syncytium-Inducing and Non-Syncytium-Inducing Capacity of Human Immunodeficiency Virus Type 1 Subtypes Other Than B: Phenotypic and Genotypic CharacteristicsF. de Wolf, Els J. M. Hogervorst, Jaap Goudsmit et al.|AIDS Research and Human Retroviruses|1994Cited by 171
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Daniel J Stieh et al.|The Lancet HIV|2020Cited by 91
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionLindsey R. Baden, Etienne Karita, Gaudensia Mutua et al.|Annals of Internal Medicine|2016Cited by 84